Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company generates news across medical device innovation, regulatory approvals, manufacturing expansions, and healthcare industry developments. As one of the world's largest medical technology manufacturers producing tens of billions of devices annually, BD's announcements often impact healthcare supply chains, public health initiatives, and clinical practice standards.
News coverage for BD typically encompasses product launches of safety-engineered medical devices, FDA clearances for new diagnostic instruments and drug delivery systems, and manufacturing capacity announcements that affect global medical supply availability. The company's role as a major supplier of syringes, needles, IV catheters, and diagnostic equipment means its production decisions can influence healthcare delivery capabilities, particularly during public health emergencies and vaccination campaigns.
Earnings reports reveal performance across BD's three business segments: Medical, Life Sciences, and Interventional. These disclosures provide insight into healthcare spending trends, adoption rates for new medical technologies, and geographic market dynamics across developed and emerging healthcare markets. Regulatory developments, including FDA warning letters, device recalls, or quality system issues, also generate significant news given the company's broad product portfolio and global manufacturing footprint.
Corporate developments such as acquisitions of medical device companies, divestitures of business units, strategic partnerships with pharmaceutical manufacturers, and manufacturing investments shape BD's competitive position. The company's interactions with group purchasing organizations, healthcare systems, and regulatory agencies produce news relevant to understanding healthcare economics and medical device industry dynamics.
Track BD news to monitor developments in medical device innovation, healthcare supply chain updates, regulatory compliance matters, and business performance across the company's medical technology portfolio. Understanding BD's announcements provides context on trends in hospital supply management, clinical diagnostics, and medication delivery technologies.
BD (NYSE:BDX) announced a strategic collaboration with the Institute for Immunology and Immune Health at the University of Pennsylvania to develop and validate a high-parameter flow cytometry panel and support a planned 1,000-patient immune profiling study expected to start this summer.
The project will use the BD FACSDiscover A8 Cell Analyzer, BD Rhapsody system, BD reagents, software and informatics; BD will manage reagents, instrumentation and spectral data algorithms while Penn will serve as scientific and clinical leads. The panel aims to measure 30+ cellular characteristics, including phosphorylation markers, and the team intends to publish a peer-reviewed manuscript.
BD (NYSE: BDX) on Dec 15, 2025 announced IVDR certification in Europe for two VIASURE assays developed by Certest Biotec for the BD MAX™ System. The certified assays are the VIASURE Respiratory Virus Extended Mix (detects SARS-CoV-2, flu A/B, RSV, parainfluenza, human coronavirus, metapneumovirus, adenovirus from one nasopharyngeal swab) and the VIASURE HSV-1, HSV-2 & Treponema pallidum assay (detects HSV-1, HSV-2 and Treponema pallidum from anogenital and oral lesion swabs).
The announcement expands BD MAX molecular respiratory and STI testing options in Europe; the BD MAX System runs up to 24 samples per run, automates extraction/amplification/detection, and delivers results in ~three hours with <1 minute hands-on time per sample.
BD (NYSE: BDX) and ChemoGLO announced a strategic collaboration to expand hazardous drug contamination testing for health care facilities and laboratories.
The partnership pairs the BD HD Check System — providing qualitative, point-of-care results in 10 minutes — with ChemoGLO's LC-MS/MS quantitative analysis, which delivers an expanded hazardous‑drug panel report within 3–5 days after sample receipt. The workflow uses BD HD Check collection kits for safe shipping to ChemoGLO for follow-up testing.
The combined approach aims to help facilities quickly identify contamination and gain deeper quantitative insights to better protect health care workers. BD and ChemoGLO will be at the ASHP Midyear Clinical Meeting in Las Vegas, Dec 6–10, 2025 (BD Booth 1017; ChemoGLO Booth 1873).
BD (NYSE:BDX) announced on Dec 3, 2025 new three- and four-laser configurations of the BD FACSDiscover A8 Cell Analyzer, expanding access to spectral and real-time cell imaging for academia, pharma and biotech.
Key features include BD SpectralFX (analyzes up to 50+ cell characteristics), BD CellView Image for high-speed spatial/morphological imaging, optional free trials and later software upgrades, and compatibility with BD sorters and new near-infrared fluorochromes. Instruments are available to order with flexible financing options.
BD (NYSE: BDX) announced the European launch of the BD Surgiphor Surgical Wound Irrigation System on November 24, 2025. The device received CE approval and is now available in select European countries. Surgiphor is a sterile, pre-mixed, ready-to-use irrigation solution that uses a trusted antiseptic preservative to help loosen and remove debris and reduce bacterial load in surgical wounds. BD says the product is designed to simplify wound irrigation, reduce preparation time, and support evidence-based practices to help lower the risk of surgical site infections and improve surgical safety.
Availability is limited to select countries in Europe; healthcare providers should contact BD sales representatives for regional access and product details.
BD (NYSE:BDX) announced a pharmacy automation partnership with Henry Ford Health on Sept. 22, 2025 to develop a hospital and community pharmacy robotic solution using the BD Rowa Vmax.
The collaboration will pilot 24/7 prescription pickup, automated high-capacity storage and refrigerated handling, real-time prescription tracking, and modular scalability to improve pharmacy staff efficiency and ensure patients leave with medications in hand at discharge or clinic visits.
BD (NYSE: BDX) announced the appointment of Robert Huffines and Jacqueline Wright to its board of directors, effective Dec. 1, 2025. The company said the additions add expertise in health care, technology, digital transformation, artificial intelligence, finance and capital markets as BD advances its strategy to be a scaled pure‑play medical technology company. BD added three new independent directors in 2025, reflecting ongoing board refreshment. Bios note Huffines' 30+ years in healthcare investment banking and board service, and Wright's 30+ years in technology and digital transformation at McKinsey and Microsoft.
BD (NYSE: BDX) announced that the CE-marked BD Onclarity HPV Assay for the BD COR and BD Viper LT systems received WHO prequalification on November 17, 2025, enabling wider use in low- and middle-income countries.
The assay detects 14 high-risk HPV types with extended genotyping (six individual types plus three genotype groups), supports self-collection including at-home where CE is recognized, and targets improved risk stratification and follow-up. The BD COR offers ~1,650-test capacity and up to 1,000 results in 24 hours; BD Viper LT provides compact, decentralized molecular testing.
BD (NYSE: BDX) announced on November 13, 2025 that Duncan Regional Hospital is the first U.S. hospital to go live with BD Alaris™ EMR Infusion Interoperability integrated with MEDITECH. The integration enables bi-directional communication between MEDITECH and Alaris infusion pumps, allowing clinicians to scan to verify patients, medications and pumps; send infusion orders from MEDITECH to pumps; and receive infusion status back into the EHR.
The rollout expands BD's market-leading interoperability—now live at more than 960 U.S. sites—to all three leading U.S. EHRs, and BD reports a pace of about 12 new site activations per month.
BD (NYSE: BDX) on Nov 12, 2025 introduced the PureWick™ Portable Collection System, a battery-powered, non-invasive urine management device designed for wheelchair users and mobile use.
Key facts: the device offers up to 8 hours battery life, is mountable or carriable, compatible with PureWick™ male and female external catheters, and is sold via PureWickAtHome.com and phone ordering. The PureWick portfolio has sold > 55 million external catheters and is used in > 4,500 hospitals and rehab facilities in the U.S.; a survey of 150 users/caregivers found > 90% would recommend the PureWick urine collection system. BD positions the portable unit to improve mobility, discretion, and skin protection for people managing urinary incontinence.
FAQ
What is the current stock price of Becton Dickinson & Co (BDX)?
What is the market cap of Becton Dickinson & Co (BDX)?
